Randomized, Double Blind, Placebo Control Trial to Evaluate the Efficacy of Astragalus Membranaceus in the Patients After Stroke With Fatigue
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01554787|
Recruitment Status : Unknown
Verified March 2012 by China Medical University Hospital.
Recruitment status was: Recruiting
First Posted : March 15, 2012
Last Update Posted : March 15, 2012
The high levels of fatigue in stroke patients without neurological impairment suggest it has a central origin rather than being the result of increased physical effort required after stroke（Winward et al., 2009）. Fatigue is different from post-stroke depression and the more serious stroke patients are more prone to fatigue（Windward et al., 2009）.
Fatigue is one of the symptoms of qi deficiency,and Astragalus membranaceus is the most effective of all traditional Chinese medicine and can tonifying middle and tonify the original qi. Therefore, the aim of this study was to investigate the efficacy of Astragalus membranaceus on post-stroke fatigue.
|Condition or disease||Intervention/treatment||Phase|
|Fatigue Stroke||Drug: Chinese Herb Astragalus membranaceus Other: Placebo||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||90 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Study Start Date :||January 2012|
|Estimated Primary Completion Date :||December 2013|
|Experimental: Chinese Herb Astragalus membranaceus||
Drug: Chinese Herb Astragalus membranaceus
Astragalus membranaceus(AM)at a rate of 2.8g three times per day
|Placebo Comparator: Placebo||
at a rate of 2.8g three times per day
- EORTC QLQ-C30 [ Time Frame: 2 year(all patients) ]
- BFI-T score [ Time Frame: 2 years(all patients) ]
- SF-36 score [ Time Frame: 2 years(all patients) ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01554787
|Contact: Chung Hsiang Liu, MD.||886-4-22052121 ext email@example.com|
|China Medical University Hospital||Recruiting|
|Contact: Chung Hsiang Liu, MD.|
|Principal Investigator: Chung Hsiang Liu, MD.|
|Principal Investigator:||Chung Hsiang Liu, MD.||China Medical University Hospital|